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Abstract
Background: Colorectal cancers (CRCs) that lack DNA mismatch repair function exhibit the microsatellite unstable
(MSI) phenotype and are characterized by the accumulation of frameshift mutations at short repetitive DNA
sequences (microsatellites). These tumors recurrently show inactivating frameshift mutations in the tumor
suppressor Transforming Growth Factor Beta Receptor Type 2 (TGFBR2) thereby abrogating downstream signaling.
How altered TGFBR2 signaling affects exosome-mediated communication between MSI tumor cells and their
environment has not been resolved. Here, we report on molecular alterations of exosomes shed by MSI cells and
the biological response evoked in recipient cells.
Methods: Exosomes were isolated and characterized by electron microscopy, nanoparticle tracking, and western
blot analysis. TGFBR2-dependent effects on the cargo and functions of exosomes were studied in a MSI CRC model
cell line enabling reconstituted and inducible TGFBR2 expression and signaling. Microsatellite frameshift mutations
in exosomal and cellular DNA were examined by PCR-based DNA fragment analysis and exosomal protein profiles
were identified by mass spectrometry. Uptake of fluorescent-labeled exosomes by hepatoma recipient cells was
monitored by confocal microscopy. TGFBR2-dependent exosomal effects on secreted cytokine levels of recipient
cells were analyzed by Luminex technology and ELISA.
Results: Frameshift mutation patterns in microsatellite stretches of TGFBR2 and other MSI target genes were found
to be reflected in the cargo of MSI CRC-derived exosomes. At the proteome level, reconstituted TGFBR2 expression
and signaling uncovered two protein subsets exclusively occurring in exosomes derived from TGFBR2-deficient
(14 proteins) or TGFBR2-proficient (five proteins) MSI donor cells. Uptake of these exosomes by recipient cells
caused increased secretion (2–6 fold) of specific cytokines (Interleukin-4, Stem Cell Factor, Platelet-derived Growth
Factor-B), depending on the TGFBR2 expression status of the tumor cell.
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Conclusion: Our results indicate that the coding MSI phenotype of DNA mismatch repair-deficient CRC cells is
maintained in their exosomal DNA. Moreover, we uncovered that a recurrent MSI tumor driver mutation like
TGFBR2 can reprogram the protein content of MSI cell-derived exosomes and in turn modulate the cytokine
secretion profile of recipient cells. Apart from its diagnostic potential, these TGFBR2-dependent exosomal molecular
and proteomic signatures might help to understand the signaling routes used by MSI tumors.
Keywords: Exosomes, Intercellular communication, Proteomics, Transforming Growth Factor Beta Receptor Type 2,
DNA mismatch repair deficiency, Microsatellite instability, Colorectal cancer
Plain English summary
A subset of colorectal cancers show the so-called
microsatellite instability (MSI) phenotype that is char-
acterized by the accumulation of tumor cell-specific
genetic alterations at repetitive DNA sequences. Like
many other normal and malignant cells, these MSI
tumor cells release 30–150 nm sized vesicles, termed
exosomes, to communicate with other cells locally and
at distant sites. How MSI tumor cell-specific genetic al-
terations in the parental cells impact the biology and
function of shedded exosomes and in turn affect re-
sponder cells remains unresolved.
To address this question, we have isolated and char-
acterized exosomes from MSI colorectal cancer cell
lines. We uncovered that the MSI phenotype of the
parental cells is shared by their secreted exosomes. It
also was observed that the expression status of a
tumor driver gene in MSI tumor cells led to specific
alterations in the protein content of the released exo-
somes which in turn elicit a biological response in re-
cipient cells by changing their cytokine secretion
profile. Hence, the described molecular and proteomic
signatures transmitted by MSI tumor cell-specific exo-
somes provide novel insights into the biological mes-
sages sent by their donor cells and might facilitate
the development of new diagnostic and therapeutic
approaches.
Background
Adaptation of tumor cells to their continuously chan-
ging microenvironment is reflected by genetic and
epigenetic alterations and usually accompanied by
significant changes in their cellular phenotype. Among
several other mechanisms, extracellular vesicle shed-
ding and release of their cargo to target cells can ac-
count for these effects [1, 2]. Exosomes constitute a
distinct subset of extracellular vesicles about 30–
150 nm in diameter and are released by all normal and
neoplastic cells. They can accommodate proteins, nu-
cleic acids, lipids, and metabolites [3] and are involved
in different biological functions like intercellular commu-
nication, coagulation, and immune response modulation.
Accumulating evidence suggests that exosomes play a key
role in cancer [4]. It has been demonstrated that cancer
cell-derived exosomes can transfer oncogenic proteins
and nucleic acids to recipient cells, thereby promoting
tumor growth, metastasis, and drug resistance [5–7].
For example, exosomes derived from breast cancer cells
but not normal cells contain the complete pre-miRNA
processing machinery which enables them to alter the
transcriptome of target cells in a Dicer-dependent man-
ner, thereby stimulating non-tumorigenic epithelial
cells to form tumors [8]. Likewise, colon cancer cell-
derived exosomes have been found to be enriched in
ΔNp73 mRNA and the proliferation potential of target
cells is greatly enhanced by incubation with ΔNp73-
containing exosomes [9]. Thus, most of the genetic al-
terations that exist in the DNA, RNA or protein of the
donor cells also occur in the exosomes derived thereof
and contribute to the pathogenesis of cancer.
The pathogenesis of DNA mismatch repair-deficient
(dMMR) colorectal cancers (CRC) has gained increasing
attention, because of distinct clinico-histopathological
and molecular features. When compared to their MMR-
proficient counterparts they have a more favorable
prognosis [10], show an altered chemo-responsiveness
[11, 12], have a lower propensity to form distant metas-
tases [13, 14], and exhibit an intense inflammatory re-
sponse with tumor-infiltrating lymphocytes [15, 16]. As a
molecular hallmark, these dMMR tumor cells accumulate
numerous somatic small insertion/deletion mutations pre-
dominantly at short, repetitive DNA sequences (microsa-
tellites), thereby manifesting the microsatellite instability
(MSI) phenotype [17, 18].
When this instability occurs at coding mononucleotide
repeats (cMNR), affected genes will generate transcripts
with premature termination codons (PTC) that are usually
recognized and degraded by the cellular nonsense-
mediated RNA decay system [19, 20], but upon translation
can give rise of truncated proteins with highly immuno-
genic frameshift peptide tails [21]. Several studies have
identified a large number of cMNR harboring genes fre-
quently affected by frameshift mutations in MSI colorectal
tumors [22, 23], but only a limited set of recurrently mu-
tated genes are considered to drive MSI tumorigenesis.
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One of these prime MSI targets is the gene encoding
the Transforming Growth Factor Beta Receptor Type 2
(TGFBR2), which is part of a key signaling pathway in
colon epithelial cells. In canonical TGFBR2-mediated
signaling, binding of the TGF-ß1 ligand to this trans-
membrane receptor causes hetero-tetramerization with
type 1 (TGFBR1) receptors, that upon phosphorylation
triggers SMAD-mediated signal propagation and execu-
tion of cell context-dependent expression programs
[24, 25]. Altered TGFBR2 signaling in tumor cells can
modulate a wide range of processes like epithelial-to-
mesenchymal transition (EMT), migration and inva-
sion, angiogenesis, immunomodulation, and cytokine
secretion. Biallelic cMNR frameshift mutations within
the TGFBR2 gene arise recurrently in most MSI colo-
rectal tumors and are considered to drive MSI
tumorigenesis [26]. In the present study, we explored
whether the cellular MSI phenotype is maintained in
exosomes and how MSI driver mutations in a major
signaling pathway, as exemplified by the TGFBR2
tumor suppressor, can alter the exosomal content of
MSI tumor cells and in turn elicit a biological re-
sponse in specific target cells. It turned out, that the
MSI status and the cMNR frameshift mutation allele
patterns of MSI colorectal cancer cells is reflected by
their shed exosomes. Moreover, using our MSI colorectal
cancer cell line model system (HCT116-TGFBR2) that en-
ables the analysis of TGFBR2-dependent cellular alter-
ations in an isogenic background [27] we uncovered
distinct differences in exosomal protein signatures de-
pending on the TGFBR2 expression status of their donor
cells. Similarly, these exosomes cause significant alter-
ations in the cytokine secretion profile of HepG2 recipient
cells in a TGFBR2-dependent manner with PDGF-B exhi-
biting the most prominent increase in protein expression
levels. These results provide strong evidence for TGFBR2
being a potent modulator of exosomal protein content
and a modulator of cytokine response in specific target
cells.
Methods
Cell culture
dMMR CRC cell lines (HCT116, RKO, LoVo) and the
MMR-proficient CRC cell line (SW948) were obtained
from ATCC. The generation of the doxycycline-inducible
cell line model system HCT116-TGFBR2 was reported
previously [27]. KM12 cells were kindly provided by I.J.
Fidler and HepG2 by K. Breuhahn. Cells were grown in
RPMI 1640 (LoVo, KM12, RKO, HepG2) or DMEM
(HCT116, HCT116-TGFBR2) medium supplemented
with 10% FBS, 100 U/ml penicillin and 100 μg/ml strepto-
mycin (Thermo Fisher Scientific Inc., USA) using standard
conditions.
Isolation of exosomes
dMMR CRC cell lines were plated on T175 flasks and
grown in complete medium as described above until
they reached approximately 80–90% confluency. Cells
were washed twice with phosphate-buffered saline (PBS)
and cultured for 16 h in minimal volumes (17 ml/T175
flask) of serum-free medium. To investigate TGFBR2-
dependent exosomal alterations, HCT116-TGFBR2 cells
were cultured in the presence of TGF-ß1 (10 ng/ml)
with or without doxycycline (Dox, 0.5 μg/ml). Cell cul-
ture media were collected and subjected to sequential
centrifugations to remove floating cells (480 × g, 4 °C,
10 min) and cellular debris (2000 × g, 4 °C, 10 min).
Supernatants were then passed through a 0.22 μm fil-
ter to reduce microparticle contamination and filtrates
were concentrated to a final volume of 1 ml by 10,000
molecular weight-cutoff Vivaspin 20 centrifugal con-
centrators (4000 × g, 4 °C, 30 min; Sartorius,
Germany). After addition of 500 μl Total Exosome
Isolation Reagent (Thermo Fisher Scientific Inc.,
USA), samples were incubated overnight at 4 °C on a
rotating wheel and then centrifuged at 10,000 x g and
4 °C for 1 h. Exosomal pellets were resuspended either
(i) in 100 μl PBS for transmission electron microscopy,
(ii) in 200 μl PBS for DNA isolation and fragment ana-
lysis, (iii) in 100 μl PBS containing 0.5% bovine serum
albumin (BSA) for CFSE-labeling/uptake experiments, or
(iv) in 60 μl RIPA buffer in the presence of protease inhib-
itors for Western blot and mass spectrometry analyses.
Isolated extracellular vesicles were stored at −80 °C.
Transmission electron microscopy
Drops of thawed exosome suspensions were left to settle
on 100 mesh formvar-coated copper grids (Plano GmbH,
Germany), contrasted with 3% aqueous uranyl acetate
(negative stain), air dried and visualized using a JEM-
1400 transmission microscope (JEOL GmbH, USA) at
80 KV, equipped with a Tietz 2 K digital camera (TVIPS,
Germany).
Western blotting
Western blot analysis was performed as described previ-
ously [27]. Briefly, 30 μg protein was separated on 4–12%
SDS-PAGE gels (Thermo Fisher Scientific Inc., USA) and
electro-blotted onto a nitrocellulose membrane. The fol-
lowing primary antibodies were used: mouse monoclonal
CD63 antibody (1:500, 4 °C, overnight; Abcam, UK),
mouse monoclonal CD9 antibody (1:200, 4 °C, overnight;
Santa Cruz, Germany), and mouse anti-ß-Actin (1:1000,
RT, 30 min; MP Biomedicals, USA). Subsequently, blots
were incubated for 1 h at RT with a sheep anti-mouse-IgG
HRP secondary antibody (1:5000; GE-Healthcare, UK).
Signals were detected using Western Lightning Plus ECL
(Perkin Elmer, USA).
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Nanoparticle tracking analysis
Size profiling of isolated vesicles was performed in a
dilution of 1:5000 by nanoparticle tracking analysis
(NTA) using Nanosight LM10 equipped with a 405 nm
laser (Malvern Instruments, UK). The analysis was
conducted according to the manufacturer’s instructions
by analyzing 30 s-measurements with a slider shutter of
1000 at five different positions per sample.
PCR-based DNA fragment analysis
Total cellular and exosomal DNA was isolated using
QIAamp DNA Mini Kit (Qiagen, Germany). After pre-
cipitation by ethanol, the cellular and exosomal DNA
was used for PCR-based frameshift analysis. PCR amp-
lification of cMNR sequences was performed using
specific primers (Additional file 1) designed with pri-
mer3 software (http://primer3.ut.ee/) and the following
cycler program: 95 °C for 10 min, followed by 40 cycles
of 95 °C for 15 s and 60 °C for 1 min and final exten-
sion for 7 min at 72 °C. Fragment analysis was carried
out on an ABI 3130xl Genetic Analyzer (Applied
Biosystems, Germany) using the Genescan Analysis
Software (Applied Biosystems, Germany).
Mass spectrometry
Sample preparation
Total protein RIPA lysates of exosomes were precipi-
tated using a methanol-chloroform-water mixture [28]
followed by in-solution tryptic digestion. Precipitated
exosomal proteins were redissolved in 10 μl 40 mM
NH4HCO3 and treated with 2 μl 10 mM dithiothreitol
(DTT) solution in 40 mM NH4HCO3 at 45 °C for 1 h
to completely reduce disulfide bonds. Afterwards, the
thiol groups were alkylated by addition of 1 μl 55 mM
iodoacetamide solution in 40 mM NH4HCO3 and
30 min incubation in the dark at 25 °C. After adding
2.5 μl DTT solution, the mixture was incubated for
15 min at 37 °C to let all iodoacetamide react with a
thiol group. Digestion was performed with 100 ng tryp-
sin (Promega, USA) in 40 mM NH4HCO3 solution
overnight at 37 °C. To stop the tryptic digestion, 7.5 μl
of 0.1% TFA were added to the sample. In total, 1/5
(i.e. 5 μl) of the sample was subjected to the nano-
Liquid Chromatography (LC) electrospray ionization
MS/MS analysis. For the analysis, four biological repli-
cates of each sample (JK2358_1–4: exosomes derived
from dTGFBR2 cells; JK2358_5–8: exosomes derived
from pTGFBR2) have been prepared.
Electrospray ionization MS/MS analysis
Tryptic peptide mixtures were separated by a nanoAc-
quity ultra-high-performance LC system. Peptides were
trapped on a nanoAcquity C18 column (180 μm×
20 mm, 5-μm particle size). The liquid chromatography
separation was performed on a C18 column (BEH
130 C18, 100 μm× 100 mm, 1.7-μm particle size)
with a flow rate of 400 nl/min. For all samples, the
chromatography was carried out using a 3 h gradient
of solvent A (98.9% water, 1% acetonitrile, 0.1% for-
mic acid) and solvent B (99.9% acetonitrile and 0.1%
formic acid) in the sequence: from 0 to 4% B in
1 min, from 4 to 30% B in 140 min, from 30 to 45%
B in 15 min, from 45 to 90% B in 5 min, 10 min at
90% B, from 90 to 0% B in 0.1 min, and 9.9 min at
0% B. The ultra-high-performance LC system was
connected online to an LTQ Orbitrap XL mass spec-
trometer (Thermo Scientific, Germany). The mass
spectrometer was operated in the sensitive mode with
the adjusted parameters: capillary voltage 2400 V; ca-
pillary temperature 200 °C; normalized collision en-
ergy 35 V; activation time 30,000 ms. Data were
obtained in scan cycles of one Fourier transform MS
scan with a resolution of 60,000 at m/z 400 and a
range from 370 to 2000 m/z in parallel with six MS/
MS scans in the ion trap of the most frequent pre-
cursor ions.
Database search and evaluation
The MS files generated by Xcalibur software (version
2.0.6) were used for database searches with the MAS-
COT search engine (version 2.4; Matrix Science)
against the Swiss-Prot database (SwissProt version
2013_02 (539165 sequences; 191456931 residues))
[29]. The taxonomy was set to “human”. The peptide
mass tolerance was set to 5 ppm and the fragment
mass tolerance was adjusted at 0.4 Dalton. Carba-
midomethylation of cystein (C) was set as a fixed
modification. Variable modifications included oxida-
tion of methionine (M) and deamidation of asparagine
(N) and glutamine (Q). One missed cleavage site in
the case of partial trypsin hydrolysis was accepted.
The false discovery rates (FDRs) at the protein and
peptide level were set to 1%. Proteins were considered
as identified, if more than one unique peptide had an
individual ion score exceeding the MASCOT identity
threshold (ion score cut-off 20). Identification under
the performed search parameters refers to a match
probability of p < 0.01, where p is the probability that
the observed match is a random event. Candidate
proteins were classified as differentially expressed (ex-
clusively in exosomes derived from dTGFBR2 or
pTGFBR2 cells), if detected in at least three of four
biological replicates. The raw data of MS proteomics
are deposited to the ProteomeXchange Consortium via
the PRIDE partner repository [30] with the project acces-
sion number: PXD005620 and project DOI: 10.6019/
PXD005620 [31].
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Fluorescent labeling of isolated exosomes
Exosomes were isolated from HCT116-TGFBR2 cells as
described above. To label intra-exosomal proteins, isolated
exosomes were incubated in 5 μM 5(6)-carboxyfluorescein
diacetate N-succinimidyl ester (CFSE; Sigma-Aldrich,
Germany) at 37 °C for 30 min in the dark. The reaction
was stopped by adding two volumes of RPMI medium.
After ultracentrifugation (120,000 × g, 4 °C, 2 h; rotor:
100.2; UZ: TLA-100.2, Beckman Coulter, Germany),
exosomes were resuspended in 50 μl cold PBS and used
directly for uptake experiments.
Tracking of exosomes uptake by confocal microscopy
HepG2 cells were seeded in 0.5 ml of exosome-depleted
medium onto a glass bottom dish (35 × 10 mm; Greiner
Bio-One International GmbH, Austria) and treated with
50 μl of CFSE-labeled exosomes overnight in the dark
at 37 °C in 5% CO2-atm. Next day, the medium was
discarded and the cells were washed with 1 ml PBS.
Uptake of exosomes by HepG2 cells was analyzed using
a Zeiss LSM 710 ConfoCor3 confocal microscope (Carl
Zeiss, Germany) equipped with an argon laser and a
Plan-Apochromat 63x/1.40 Oil DIC objective (Carl
Zeiss, Germany). Excitation was performed at 488 nm
and detection was executed in a filter range of 493 to
630 nm. Images were analyzed using IMAGE J-Fiji soft-
ware [32].
Luminex-based cytokine profiling of HepG2 cells
HepG2 cells (8.5 × 104 cells/cm2) were cultured in 6-
well plates for 24 h. Cells were washed with PBS and
grown in exosome-depleted 1% FBS-containing RPMI
medium in the presence of HCT116-TGFBR2-derived
exosomes (20 μg/ml of exosomal protein determined by
Bradford Red assay). After 24 h of exosomal exposure,
cell culture supernatants were collected and centrifuged
(1000 × g, 4 °C, 15 min) and cell numbers in each well
were counted. Supernatants were analyzed for 50 secreted
cytokines and chemokines using pre-designed Bio-Plex
panels (Bio-Plex Pro Human Cytokine 21-, 27-Plex Panel
and ICAM-1-, VCAM-1 Assay; Bio-Rad Laboratories
GmbH, Germany) according to the manufacturer’s
protocol. The standard curve was prepared as a System;
Bio-Rad Laboratories GmbH, Germany) with a 532 nm
reporter laser and 635 nm classification laser. Cytokine
concentrations [pg/ml] were calculated with Bio-Plex
Manager software (version 4.0; Bio-Rad Laboratories
GmbH, Germany) by optimizing the standard curves
for each cytokine. Cytokine concentrations were nor-
malized to corresponding cell numbers and fold
changes (pTGFBR2/dTGFBR2) calculated from normal-
ized values.
PDGF-B enzyme-linked immunosorbent assay (ELISA)
HepG2 cells were seeded as biological duplicates in 12-
well plates at densities of 8.5 × 104 cells/cm2. Cells were
grown in the presence of exosomes as described for the
cytokine profiling. Supernatants were collected, centri-
fuged (1000 × g, 4 °C, 15 min) and the cell numbers of
each well were counted. Supernatants were analyzed
using the human PDGF-B ELISA (BlueGene Biotech
CO., China) according to the manufacturer’s protocol.
The OD of each sample was normalized to the corre-
sponding cell number. After subtracting blank value
(medium without cells), log10OD values were calculated.
For analyzing the concentration [pg/ml] of each sample in
accordance with the standard curve, the log10OD-values
of the biological replicates were averaged arithmetically.
Finally, fold changes were determined by calculating a
concentration ratio (pTGFBR2/dTGFBR2).
Results
Characterization of extracellular vesicles Isolated from
dMMR colorectal cancer cell lines
To determine the identity of isolated nanovesicles,
three different approaches were pursued. First, trans-
mission electron microscopy (TEM) was used for
examining the structure of the vesicles. As indicated in
Fig. 1a, representative exosomes consisted of cup-
shaped closed vesicles that ranged in diameter from 30
to 120 nm and lacked apoptotic bodies and cellular
debris. The exosomal appearance was observed in prep-
arations from all dMMR cell lines (HCT116, LoVo,
KM12, RKO, HCT116-TGFBR2). Second, Western blot
analysis revealed expression of the exosomal marker
proteins CD63 and CD9 in protein lysates of exosomes
but not in whole cell lysates of HCT116-TGFBR2 donor
cells (Fig. 1b). Third, nanoparticle tracking analysis
(NTA) confirmed the size distribution of isolated nano-
vesicles. As shown in Fig. 1c, the major proportion of
isolated vesicles ranged in a mono-peak fashion from
50 to 150 nm in diameter. These results indicate the
isolation of bona fide exosomes from different dMMR
donor cells and these exosomes were used for further
investigations.
Exosomes from different dMMR CRC cell lines accumulate
frameshift mutations in coding mononucleotide repeats
In dMMR cells, numerous cMNR-harboring genes are
affected by insertion/deletion mutations that constitute
the MSI phenotype. Whether genomic DNA harboring
such frameshift mutations are encased and detectable in
exosomes secreted by dMMR cells is unresolved. There-
fore, we isolated exosomal as well as cellular DNA from
four dMMR CRC cell lines with known cMNR mutation
status (Additional file 2) and examined the cMNR
frameshift mutation pattern of three representative MSI
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target genes (TGFBR2 [A10], LMAN1 [A9], MARCKS
[A11]). The allele profile of the CRC cell line SW948
served as control because these MMR-proficient (pMMR)
and microsatellite stable cells lack cMNR mutations
(Fig. 2). Using PCR-based DNA fragment analysis, allelic
length shifts (-1/-2) affecting three representative cMNR
gene sequences (MARCKS, TGFBR2, LMAN1) were ob-
served in exosomes of four different dMMR cell lines. In
terms of TGFBR2 and LMAN1, we found almost identical
mutant and/or wildtype alleles in MSI cell lines and their
derived exosomes. However, specific differences between
the exosomal and cellular mutant allele pattern became
apparent and are highlighted by circled areas in Fig. 2. For
example, only mutant alleles (-1 deletions) affecting the
A11-cMNR of the MARCKS gene were detected in the
exosomes of 3/4 cell lines (HCT116, LoVo, RKO),
whereas cellular DNA showed either wildtype alleles
(HCT116, KM12, RKO) or a mixed normal and mutant
allele pattern (LoVo). Similarly, exosomes of 3/4 cell lines
(HCT116, LoVo, RKO) only contained mutant (-1)
LMAN1 alleles, while identical mutant or wildtype
LMAN1 allele pattern were observed among exosomal
and cellular DNA in 3/4 cell lines (HCT116, KM12,
LoVo). Interestingly, the most consistent exosomal and
cellular cMNR pattern was identified for the TGFBR2
gene. All dMMR cell lines exclusively exhibited TGFBR2
frameshift mutations (−1, −2) and each cell line main-
tained identical allele pattern intracellularly and within
exosomes. These data indicate that the genomic MSI
phenotype of dMMR CRC cell lines principally is pre-
served in the exosomes released by these cells.
Expression status of the MSI target gene TGFBR2modulates
the exosomal proteome of dMMR HCT116 CRC cells
Since TGFBR2 cMNR frameshift mutations are considered
drivers of dMMR tumors and HCT116 cells and derived
exosomes both express only frameshift-mutated and no
wildtype TGBFR2 gene pattern, we investigated whether
the TGFBR2 expression status might affect the exosomal
proteome composition of HCT116 cells. To address this
question, we used our previously established model sys-
tem of HCT116-TGFBR2 cells that have been genetically
modified to regulate TGFBR2 expression and signaling in
a doxycycline-dependent manner [27]. Exosomes were
Fig. 1 Characterization of isolated exosomes. a Transmission electron microscopy (TEM) illustrates the size and shape of exosomes (indicated by
arrows) isolated from different MSI colorectal cancer cell lines (HCT116, LoVo, KM12, RKO) and from the model cell line HCT116-TGFBR2 (pTGFBR2:
TGFBR2-proficient, dTGFBR2: TGFBR2-deficient). Smaller particles represent vesicle fragments resulting from the isolation procedure. Scale bar = 100 nm.
b Western blot analysis shows tetraspanin (CD63, CD9) marker expression for whole cell lysates (WCL) of HCT116-TGFBR2 donor cells and lysates of
derived exosomes (EXO). ß-actin served as a loading control. c Nanoparticle tracking analysis (NTA) indicates size distribution for vesicles isolated from
HCT116-TGFBR2 cells (representative of six independent experiments)
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isolated from the supernatant of HCT116-TGFBR2 cells
grown in the absence (dTGFBR2) or presence (pTGFBR2)
of doxycycline and total exosomal protein lysates were ana-
lyzed by mass spectrometry. In total, 1453 different exoso-
mal proteins have been identified. Among these, 1089
overlapping proteins were detected in exosomes derived
from both pTGFBR2 and dTGFBR2 HCT116 cells and
hence were considered unaffected by TGFBR2 expression
of the dMMR donor cell. This shared exosomal proteome
encompassed the top 25 exosomal cargo proteins that often
have been identified in previous studies (www.exocarta.org).
Furthermore, classical exosomal marker proteins like
CD63, CD81, and TSG101 have been detected under both
conditions thereby confirming the validity of our experi-
mental approach.
In contrast to this shared proteome, a subset of 364 exo-
somal proteins was found to be associated with the
TGFBR2 expression status of HCT116-TGFBR2 donor
cells. In particular, 167 exosomal proteins were identified
to be exclusively expressed in exosomes derived from
dTGFBR2 cells, whereas 197 proteins remained restricted
to exosomal vesicles shed by pTGFBR2 donor cells (Fig. 3).
Applying further specific selection criteria revealed a small
subset of exosomal proteins (n = 19) that presented con-
sistent (3/4 biological replicates) TGFBR2-dependency
and hence marked the exclusive TGFBR2-dependent exo-
somal proteome (Fig. 3, Table 1). The majority of these
proteins were found to be expressed solely in dTGFBR2
exosomes (14/19) and thus might have potential impact
on the pathogenesis of most MSI tumors that lack normal
TGFBR2 function. Identified proteins include factors in-
volved in RNA binding/processing, and transcriptional
regulation (U2AF1, PCBP3), migration, extracellular
matrix remodeling (COL3A1), epithelial-to-mesenchymal
transition (FAMC3), chromatin structure (HIST2H2AB),
cell junction structure (TJP1), regulators of cytoskeletal
organization (LRRFIP1, INVS), nuclear/mitochondrial im-
port (LRRC59, TOMM70A), DNA replication (RPA2),
and vesicular trafficking (SYT5) as well as enzymes for
purine nucleotide synthesis (GMPR2, PRPSAP1).
In contrast, a much smaller number of exosomal
proteins (5/19) were detected exclusively in vesicles se-
creted by pTGFBR2 HCT116 cells. Among these pro-
teins were the pro-inflammatory cytokine interleukin
18 (IL-18) as well as four different enzymes like the
beta 1,3-N-acetylglucosaminyltransferase 7 (B3GNT7),
the mitochondrial glutamate dehydrogenase 1 (GLUD1),
the lysyl oxidase-like 4 protein (LOXL4), and the
ubiquitin-specific protease 6 (USP6). These observations
suggest that the TGFBR2 expression status of MSI tumor
cells determines the expression of specific protein subsets
in derived exosomes that are expected to elicit TGFBR2-
dependent responses in recipient cells.
Exosomes of MSI tumor cells cause alterations in the
cytokine profile of HepG2 target cells
Since mutation in the TGF-ß pathway are among the
most frequent genetic alterations found in CRCs and
these tumors frequently metastasize to the liver, we
examined the ability of HCT116-TGFBR2-derived
exosomes to induce a biological response in HepG2 re-
cipient cells. First, we analyzed the uptake of exosomes
by these target cells using CFSE-labeled exosomes
derived from HCT116-TGFBR2 cells. CFSE is a mem-
brane permeable dye, which allows exosomal esterases
to hydrolyze the dye by removing diacetate residues
Fig. 2 Gene-specific cMNR frameshift mutations in exosomal and
cellular DNA of different MSI CRC cell lines. Frameshift mutations are
recognized as shifts in allele length as determined by DNA fragment
analysis. In the reference cMNR peak pattern of the microsatellite
stable cell line SW948 (control) the highest peak refers to the normal
wildtype (wt) allele length (red vertical line; reference mark), whereas
additional peaks represent PCR-associated artefact peaks. Allele
length shifts (-1, -2) were scored if novel peaks were obtained in cell
lines compared to the microsatellite stable control SW948 cell line,
or if the ratio of peak areas of corresponding peaks in cell lines
and normal control revealed values ≤0.5 or ≥2. Differences
between exosomal and cellular mutant allele pattern (circled)
are indicated. Allele sizes are given by numbers
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intra-exosomally. This reaction activates the green
fluorescence of CFSE that is coupled to the amino ends
of exosomal proteins. The appearance of green-
fluorescent exosome-derived proteins inside of HepG2
cells was monitored by confocal microscopy (Fig. 4,
Additional file 3).
These experiments clearly demonstrate the transmis-
sion of exosomal cargo proteins to HepG2 cells. This
exosomal delivery of bioactive molecules is powerful to
modulate various processes in recipient cells. One pro-
nounced effect is the ability of exosomes to modify the
spectrum of secreted cytokines upon cargo transmission.
For example, it is known that exosomes derived from
lung cancer cells can stimulate pro-inflammatory cyto-
kine production in mesenchymal cells and hence favor-
ing a tumor supportive milieu [33]. Since exosomes are
known to modulate the spectrum of secreted cytokines
in recipient cells, HepG2 cells were exposed to exosomes
and any changes in the protein levels of 50 different se-
creted cytokines and chemokines were determined by
Luminex technology.
As shown in Table 2, several cytokines exhibited sig-
nificantly decreased or increased expression levels (cut
off >1.5 fold) in a TGFBR2-dependent manner. Apart
from IL-4 (2-fold) and SCF (2.5-fold), the secretion of
Platelet-derived Growth Factor-B (PDGF-B) showed the
most prominent TGFBR2-dependent response (6-fold)
after exosomal exposure. Using a PDGF-B specific
ELISA as an alternative method, confirmed the results
obtained by Luminex assay. However, the PDGF-B con-
centration in the supernatant of HepG2 cells exposed
to exosomes from dTGFBR2 cells was twice as high in
the ELISA assay compared to the Luminex assay
(87.61 pg/ml and 40.47 pg/ml, respectively) resulting in
a decreased observed ratio of 3-fold (Table 3).
In summary, these results demonstrate that the donor
cell-dependent TGFBR2 expression status determines
the cargo composition of secreted exosomes and that
these exosomes are capable to modulate the biological/
cytokine local environment of recipient cells.
Discussion
In this study, we show for the first time that exosomes
harbor the same gene-specific cMNR frameshift muta-
tions that have been identified in their cells of origin.
One prominent example is the TGFBR2 gene, a recur-
rently mutated driver of MSI tumorigenesis. Although
detectable at the DNA level, we did not observe any
frameshift proteins in the exosomal proteome, which is
well in line with previous studies from us and others
that failed to detect such truncated proteins in total cell
lysates from various dMMR MSI tumor cell lines [34].
The genetic alterations, i.e. coding microsatellite muta-
tions, that we have identified in the exosomes of
dMMR tumor cells are MSI tumor-specific and reflect
the mutation profile of the donor cells. Preliminary
Fig. 3 TGFBR2-dependent exosomal proteome profile. Numbers refer to exosomal proteins that comprise the total proteome (n = 1453) or
define distinct protein subsets, whose expression is either shared by (n = 1089) or restricted to exosomes released by TGFBR2-deficient
(n = 167) or TGFBR2-proficient (n = 197) donor cells. From these two latter proteomes two highly specific protein subsets emerged based on
more stringent expression criteria (expression in at least three of four biological replicates, see Methods). Individual protein descriptions and
gene names are listed
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experiments suggest that this also applies to diagnostic
microsatellite markers routinely used for MSI classifica-
tion of tumor specimens (Fricke et al., unpublished
data). Evidently, this indicates the potential clinical and
diagnostic utility of MSI-tumor cell derived exosomes.
So far, our findings only apply to established MSI
colorectal cancer cell lines and certainly need to be
confirmed in exosomes isolated from liquid biopsies of
MSI tumor patients. Building up on our findings, exo-
somes from cultured MSI cell lines might prove useful
to define assay thresholds for the detection of cMNR
mutations in specific MSI driver genes. Moreover, mon-
itoring of exosomal MSI profiles might facilitate the de-
velopment of strategies for enrichment of MSI-tumor
specific exosomes.
Apart from this MSI-specific molecular fingerprint of
exosomes, our results also provide experimental evi-
dence for alterations at the proteome level. This was
observed by focusing on the TGFBR2 signal transducer,
a frequent mutation target and driver of MSI colorectal
tumorigenesis [26, 35]. The results obtained in this
study, clearly shows that the TGFBR2 expression/signaling
status in the parental cells determined the protein profile
of exosomes secreted by these cells. Although the results
of our mass spectrometry data revealed no quantitative
information, four enzymes (B3GNT7, GLUD1, LOXL4,
USP6) and one pro-inflammatory cytokine (IL-18)
were exclusively identified in exosomes released from
pTGFBR2 cells. The cytokine IL-18 is a mediator of
inflammation and an interferon-gamma-inducing fac-
tor that is involved in various processes of epithelial
repair and collagen production that is emphasized by
the prevention of TGF-ß-induced collagen gene ex-
pression due to IL-18 activity [36]. Moreover, IL-18 is
a mediator of immune responses to eliminate cancer
cells effectively [37]. However, IL-18 can also promote
tumorigenesis by inducing angiogenesis, migration,
metastasis, proliferation, and immune-escape [38, 39].
Apart from IL-18, the enzyme beta 1,3-N-acetylglucosa-
minyltransferase 7 (B3GNT7) was detected specifically in
exosomes derived from pTGFBR2 HCT116-TGFBR2 cells.
It has been reported that B3GNT7 is abundantly
expressed in normal colon cells and significantly sup-
pressed in colon cancer tissues by epigenetic alterations
with effects on the metastatic spread potential [40]. Migra-
tory and metastatic behavior of cancer cells can be further
influenced by the lysyl oxidase-like 4 protein (LOXL4), an
enzyme that is highly involved in the biogenesis of
connective tissue and matrix re-modelling [41] and which
has been identified as a protein in TGFBR2 expressing
cell-derived exosomes. Another enzyme that is solely
expressed in a pTGFBR2 manner is mitochondrial
glutamate dehydrogenase 1 (GLUD1). This enzyme is in-
volved in various metabolic processes and associated with
poor prognosis in CRC [42]. Aberrant energy metabolism
is a hallmark of many cancer cells [43] and plays a role in
colorectal tumorigenesis. Recently, it was shown that
over-expression of glutamate dehydrogenase (GDH) is
associated with CRC metastasis and poor prognosis [44].
Finally, the expression of the enzyme ubiquitin-specific
protease 6 (USP6) was exclusively identified in a pTGFBR2
fashion. USP6 can exert different functions by acting as an
oncogene, promoting WNT signaling or modulating migra-
tion and cytokinesis [45, 46].
A larger subset of 14 proteins has been detected only in
exosomes derived from dTGFBR2 cells. This protein sub-
set is of particular clinical interest because it should reflect
more accurately the situation existing in most primary
MSI colorectal tumors with recurrent loss of TGFBR2
Fig. 4 Uptake of exosomes by HepG2 recipient cells. HCT116-TGFBR2
derived exosomes were labeled with CFSE (green-fluorescent dye) and
their uptake by HepG2 recipient cells was monitored by confocal
microscopy. Scale bar = 10 μm
Table 2 Luminex assay-based analysis of cytokine and chemokine secretion levels in response to exosomal exposure
Cytokine/Chemokine concentration [pg/ml]
IL-4 IL-9 IL-10 IL-17 G-CSF IP-10 PDGF-B TNF-a MIF SCF
pTGFBR2 0.92 6.21 47.03 23.98 18.90 6.64 255.93 13.62 589.72 85.33
dTGFBR2 0.46 3.73 31.42 15.25 10.06 3.83 40.47 8.53 333.29 33.80
Fold change (pTGFBR2/dTGFBR2) 2.00 1.66 1.50 1.57 1.88 1.73 6.32 1.60 1.77 2.52
Fold change values indicate the ratio of secreted cytokine levels by HepG2 recipient cells upon exposure to exosomes derived from pTGFBR2 HCT116 cells in
comparison to exosomes isolated from dTGFBR2 donor cells. G-SCF: Granulocyte Colony Stimulating Growth Factor; IP-10: Interferon-Gamma-Inducible Protein 10;
PDGF-B: Platelet-derived Growth Factor-B; MIF: Macrophage Migration Inhibitory Factor; SCF: Stem Cell Factor
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function. The majority of these candidate proteins are
involved in migratory processes including EMT. For ex-
ample, the candidate protein Leucine-rich repeat fightless-
interacting protein 1 (LRRFIP1) is known to play a pivotal
role in cytoskeletal organization. Using Vesiclepdia and
Exocarta Databases [47, 48], this protein has already been
identified in the cargo of CRC-derived exosomes [49]. The
function of LRRFIP1 in cellular polarity/organisation is ex-
emplified by a recent study that demonstrated LRRFIP1-
stimulated CRC metastasis and invasion of hepatocytes
through integrin-dependent RhoA activation [50]. Inter-
estingly, RhoA can also be activated by Collagen alpha-
1(III) chain (COL3A1) [51], another candidate exclusively
identified from the cargo of exosomes derived from
dTGFBR2 cells. The COL3A1 protein is upregulated in
advanced ovarian carcinoma [52] and a known stimulator
of growth acceleration in human osteoblastic cells [53].
The small GTPase RhoA is involved in various cellular
processes and a prominent regulatory factor of cytoskeletal
dynamics by the induction of stress fibers [54]. Further-
more, RhoA is considered as an essential driver of TGF-ß
induced EMT [55].
Further candidates include the FAM3C protein, a
promoter of EMT and metastatic progression [56, 57]
that has previously been detected in exosomes from
other CRC cell lines [49]. Studies have shown that cyto-
plasmic FAM3C expression might serve as a prognostic
factor in colorectal malignancies [58]. Moreover, it has
been proposed that elevated concentrations of FAM3C
in the secretome of highly autophagic melanoma cell lines
could serve as candidate autophagy biomarker [59]. The
expression and metastatic proficiency of FAM3C is further
regulated by TGF-ß at a post-transcriptional level [57, 60].
Another candidate protein linked to cellular polarity
and cell-to-cell contacts is the tight junction protein ZO-1
(TJP1) that is also exclusively expressed in the dTGFBR2
exosomal proteome. Recently, it was shown that TGF-ß
increases the expression of TJP1 and enhances cell motil-
ity of lung cancer cells [61]. Expression of the Inversin
(INVS) protein also was restricted to exosomes derived
from dTGFBR2 cells. Concerning the role of INVS in the
organization of the cytoskeleton, it has been suggested
that INVS modulates cellular polarity through positioning
the mitotic spindle and at least partially by transcriptional
regulation of genes involved in WNT signaling and path-
ways associated with the maintenance of the actin
cytoskeleton/network and the migratory cellular potential
[62, 63]. In another study, the migratory and metastatic
potential of breast cancer is also correlated with another
candidate protein, Leucine-rich-repeat-containing protein
59 (LRRC59), uncovered specially in the exosomal cargo
derived from dTGFBR2 cells [64]. Although not yet con-
firmed by functional studies, our identified candidates
suggest that exosomes derived from dTGFBR2 MSI
CRC cells might modulate the migratory potential and/
or cytokine profile of target cells.
Target cell changes due to exosomal exposure have
been well described. For example, HepG2 cells can serve
as target cells for exosomes derived from CRC cells [65].
Moreover, it was shown that exosomes derived from
SW480 CRC cells are capable to stimulate the migratory
behavior and thus driving cellular alterations of HepG2
cells [66]. When we examined HepG2 target cells that
have been exposed to HCT116-TGFBR2 derived exo-
somes no obvious morphological changes were observed.
Instead, our experiments revealed major differences in
the cytokine profile in response to exosomal exposure.
Depending on the TGFBR2 expression/signaling status
of HCT116-TGFBR2 donor cells, exosomes-treated
HepG2 target cells exhibited significantly increased
secretion of interleukin-4 (2-fold, IL-4), stem cell factor
(2.5-fold, SCF) and Platelet-derived Growth Factor-B
(6-fold, PDGF-B). Although previous research could
not observe any IL-4-specific cytokine concentration in
liver tissue or liver metastasis [67], our results indicate
that transmission of exosomes derived from HCT116-
TGFBR2 CRC cells impact IL-4 secretion of recipient
HepG2 cells in a TGFBR2-dependent fashion. For
PDGF-B, the biological response was being validated by
ELISA assay (3-fold). The observed difference in the ra-
tio between Luminex and ELISA methodology might
relate to different assay reagents such as the capture
and reporter antibodies [68].
The exact mechanism how TGFBR2 reconstitution in
the donor cells elicits exosome-linked PDGF-B release in
HepG2 target cells is still unclear. From our previous
work, we know that reconstituted TGFBR2 as well as
ACVR2 signaling can cause an upregulation of PDGF-B
at the transcriptional level in the HCT116 cell line
model system [69]. Also, preliminary evidence suggests
that PDGF-B transcripts are more abundant in exosomes
of pTGFBR2 compared to dTGFBR2 HCT116 cells.
However, it is not demonstrated by our experiments if
these transcripts account for the high levels of PDGF-B
secretion from HepG2 target cells. Metabolic labeling
experiments could resolve whether this is attributable to
exosomal cargo protein delivery to or de novo protein
synthesis in recipient cells. Furthermore, the results ob-
tained from HepG2 cells need to be validated in primary
hepatocytes.
Table 3 ELISA-based validation of PDGF-B secretion
PDGF-B concentration [pg/ml]
pTGFBR2 263.28
dTGFBR2 87.61
Fold change (pTGFBR2/dTGFBR2) 3.01
Validation of PDGF-B secretion by HepG2 cells in response to exosomal treatment
in a TGFBR2-dependent manner
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Several studies have shown that PDGF signaling can
contribute to hepatocellular and colorectal tumor biology.
For example, PDGF plays a fundamental role in the initi-
ation of TGF-ß-mediated hepatocellular EMT [70]. Also,
in colorectal tumors, expression of PDGF receptors is as-
sociated with a high metastatic spread potential [71] and
expression of the PDGF-B receptor might contribute to
aggressive phenotypes of colorectal tumors with mesen-
chymal characteristics and enhanced metastatic properties
[72]. Moreover, increased levels of PDGF-B have been de-
tected in the plasma of colorectal tumor patients [73].
Clearly, the in vitro model system used in the present
study is limited to uncover the biological consequences as-
sociated with increased levels of cytokines and growth fac-
tors like PDGF-B and how exosomal cargo might shape
local and distal environments for the benefit of primary
MSI tumors. However, our data strongly suggest that
TGFBR2-dependent reprogramming of exosomal cargo
can convey MSI tumor cell-specific biological properties
to specific target cells.
Conclusion
In conclusion, our data demonstrate that the coding MSI
phenotype of dMMR cells is maintained in their secreted
exosomes and a recurrent MSI driver mutation not only
determines the protein content of MSI exosomes but also
alters the cytokine profile of HepG2 recipient cells. Hence,
MSI exosomes most likely elicit similar alterations in
other potential target cells of endothelial, mesenchymal or
hematopoietic origin which, altogether, might provide
some mechanistic insights into the specific clinic-
histopathological features of these MSI malignancies.
Finally, the MSI- and/or TGFBR2-dependent proteome of
serum exosomes of MSI tumor patients could serve as a
novel source of MSI-specific diagnostic markers.
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